Vamil Divan

Stock Analyst at Guggenheim

(3)
# 460
Out of 5,269 analysts
264
Total ratings
58.25%
Success rate
36.85%
Average return
43 Stocks
Name Action Price Target Current % Upside Ratings Updated
Vera Therapeutics
Maintains: Strong Buy
59 61
28.98 110.49% 5 Feb 27, 2025
Insmed
Reiterates: Buy
101 101
78.5 28.66% 6 Feb 25, 2025
Merck & Co
Maintains: Buy
122 115
92.29 24.61% 8 Feb 12, 2025
Pfizer
Reiterates: Buy
33 33
26.44 24.81% 15 Feb 10, 2025
AbbVie
Maintains: Strong Buy
212 214
210.27 1.77% 20 Feb 3, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
162 166
166.39 -0.23% 12 Feb 3, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
n/a
n/a n/a 5 Jan 17, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
7 4
n/a n/a 6 Dec 10, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
10 10
3.62 176.24% 2 Dec 3, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
23 41
20.86 96.55% 7 Oct 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
6
1.21 395.87% 1 Sep 10, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 2 Jun 18, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
77 77
59.92 28.5% 8 Apr 23, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
55
n/a n/a 1 Apr 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
245 330
n/a n/a 7 Jan 26, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
19 20
7.28 174.73% 9 Sep 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
21 18
n/a n/a 2 Aug 18, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
26
0.26 9900% 2 Jun 15, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
35 40
n/a n/a 3 Jun 12, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
8 9
1.02 782.35% 2 Apr 3, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Neutral
n/a
n/a n/a 1 Mar 1, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
13 2
n/a n/a 5 Nov 15, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
27 19
18.66 1.82% 7 Aug 10, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
95 98
116.71 -16.03% 8 Aug 8, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
36 34
34.6 -1.73% 7 Jul 28, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
20 10
1.74 474.71% 3 May 25, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
51 49
127.51 -61.57% 3 May 3, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
315 356
922.78 -61.42% 15 May 2, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
8 6
3.76 59.57% 1 Mar 16, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
144 154
34.35 348.33% 9 Mar 3, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
15
14.47 3.66% 5 May 6, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 6 Dec 13, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
7 4
n/a n/a 6 Nov 8, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
11 19
n/a n/a 8 Sep 17, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Neutral
35
n/a n/a 13 Aug 5, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Neutral
n/a
n/a n/a 13 Jul 10, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Outperform
36 30
n/a n/a 4 May 21, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
161 155
n/a n/a 10 Mar 7, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Outperform
15
4.12 264.08% 4 Aug 15, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
58 61
59.58 2.38% 5 Jul 27, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
103
1.7 5958.82% 3 Jan 17, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
45 55
n/a n/a 1 Sep 19, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Outperform
66 120
n/a n/a 4 Dec 20, 2016